U.S. patents available from 1976 to present.
U.S. patent applications available from 2005 to present.

Method of attenuating nerve injury induced pain

Patent 5376662 Issued on December 27, 1994. Estimated Expiration Date: Icon_subject December 8, 2013. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.

Patent References

1,2,3,4,5,6-Hexahydro-2,6-methano-3-benzazocines
Patent #: 4105659
Issued on: 08/08/1978
Inventor: Archer

Analgesic compositions
Patent #: 4582835
Issued on: 04/15/1986
Inventor: Lewis ,   et al.

Substituted benzoate ester prodrug derivatives of 3-hydroxymorphinans, which are analgesics or narcotic antagonists
Patent #: 4668685
Issued on: 05/26/1987
Inventor: Shami

Use of prodrugs of 3-hydroxymorphinans to prevent bitter taste upon buccal, nasal or sublingual administration
Patent #: 4673679
Issued on: 06/16/1987
Inventor: Aungst ,   et al.

N-oxide prodrug derivatives of 3-hydroxy morphinans and partial morphinans having improved oral bioavailability, pharmaceutical compositions, and processes
Patent #: 4722928
Issued on: 02/02/1988
Inventor: Boswell ,   et al.

Inducing analgesia by implantation of cells releasing neuroactive substances
Patent #: 4753635
Issued on: 06/28/1988
Inventor: Sagen ,   et al.

Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists
Patent #: 4760069
Issued on: 07/26/1988
Inventor: Rzeszotarski ,   et al.

Method of treating patients suffering from chronic pain or chronic cough
Patent #: 4769372
Issued on: 09/06/1988
Inventor: Kreek

Method of treating patients suffering from chronic pain or chronic cough
Patent #: 4785000
Issued on: 11/15/1988
Inventor: Kreek ,   et al.

Method of treatment for autoimmune diseases
Patent #: 4857533
Issued on: 08/15/1989
Inventor: Sherman ,   et al.

More ...

Inventor

Application

No. 163930 filed on 12/08/1993

US Classes:

514/282One of the five cyclos is five-membered and includes ring chalcogen (e.g., codeine, morphine, etc.)

Examiners

Primary: Richter, Johann
Assistant: Hydorn, Michael B.

Attorney, Agent or Firm

International Class

A61K 031/485

Abstract

The specification discloses a method of treating a human or animal patient suffering from a pain syndrome secondary to nerve injury comprising daily administration to such patient of from about 0.4 milligrams to about 2.0 milligrams of the opiate-receptor antagonist naloxone for a treatment period of from around 3 months to around 12 months, depending upon the patient's needs. Delivery is preferably at or near the nerve injury site by a number of conventional injection methods.

Other References

  • "A Randomized, Controlled Trail of Methylprednisolone or Naloxone in the Treatment of Acute Spinal-Cord Injury", vol. 322, New Eng. J. Med., (May 1990), pp. 1405-1411, Bracken et al
  • "Opiate-Receptor Antagonist Nalmefene Improves Neurological Recovery after Traumatic Spinal Cord Injury in Rates through a Central Mechanism", vol. 245, J. Pharmacology & Experimental Therapeutics, 742-48 (1988), Faden et al
  • "111-Prostaglandin Hyperalgesia: Relevance of the Peripheral Effect for the Analgesic Action of Opioid-Antagonists", Prostaglandins, Aug. 1979, vol. 18, No. 2, pp. 201-208, Ferreira et al
  • "Site of Analgesic Action of Aspirin-like Drugs and Opioids", In Mechanisms of Pain and Analgesic Compounds, New York: Raven Press pp. 309-321, Ferreira, 1979
  • "Endogenous Opiates and Nociception: A Possible Functional Role in Both Pain Inhibition and Detection as Revealed by Intrathecal Naloxone", Neuroscience Letters, vol. 24 (1981) pp. 161-164, Dickenson et al
  • "Effect of Naloxone Upon Diffuse Noxious Inhibitory Controls (DNIC) in the Rat", Brain Research vol. 240 (1981) 387-402, Le Bars et al
  • "Reaction Thresholds to Pressure in Edematous Hindpaws of Rates and Responses to Analgesic Drugs", The Journal of Pharmacology and Experimental Therapeutics vol. 150, No. 1, pp. 165-171 Winter et al
  • "Analgesia Produced by Low Doses of the Opiate Antagonist Naloxone in Arthritic Rats is Reduced in Morphine-Tolerant Animals", Brian Research, vol. 371 (1986), pp. 37-41 Kayser et al
  • "Naloxone dose dependently produces analgesia and hyperalgesia in postoperative pain", Nature, vol. 278, (1979), pp. 740-741, Levine et al
  • "Local Inhibition of Inflammatory Pain by Naloxone and its N-Methyl Quaternary Analogue," European Journal of Pharmacology, vol. 96, pp. 277-283, Rios et al., 1983
  • "Analgesia and hyperalgesia produced in the rat by intrathecal naloxone", Brain Research, vol. 189 (1980), pp. 593-597, Woolf
  • "Behavorial evidence for a bidirectional effect of systemic naloxone in a model of experimental neuropathy in the rat", Brain Research, vol. 494 (1989), pp. 276-384, Attal et al
  • "Behavioural and electrophysiological studies on the paradoxial antinociceptive effects of an extremely low dose of naloxone in an animal model of acute and localized inflammation", Exp Brain Res (1988) pp. 402-410 Kayser et al
  • "II-Prostaglandin Hyperalgesia: The Peripheral Analgesic Activity of Morphine, Enkephalins and Opioid Antagonists", Prostaglandins, vol. 18, pp. 191-200, Ferreira et al. 1979
  • "I-Prostaglandin Hyperalgesia, A cAMP/CA2+ Dependent Process", Prostaglandins, vol. 18, No. 2 (1979), pp. 179-190, Ferreira et al
  • "Drug Interaction in the Field of Analgesic Drugs", Proceedings of the Royal Society of Medicine, vol. 58, pp. 978-983, Lasagne, 1978
  • "Naloxone alters pain perception and somatosensory evoked potentials in normal subjects", Nature, vol. 270 (1977), pp. 620-622, Buchsbaum et al
  • "Antinociceptive Activity of Narcotic Agonist and Partial Agonist Analgesics and other Agents in the Tail-Immersion Test in Mice and Rats", Neuropharmacology, vol. 15 (1976), pp. 683-688, Sewell et al
  • "Inhibition of Inflammatory Pain by Naloxone and its N Methyl Quaternary Analogue", Life Sciences, vol. 31 (1982), pp. 1209-1212, Rios et al
  • "Dose-dependent analgesic and hyperalgesic effects of systemic naloxone in arthritic rats", Brain Research, vol. 226 (1981) pp. 344-348, Kayser et al
  • "Opioid and Nonopioid Mechanism May Contribute to Dynorphin's Pathophysiological Actions in Spinal Cord Injury", Annals of Neurology, vol. 27, No. 1 (1990), pp. 67-74, Faden
  • "Dynorphin A-(1-17) Induces Alterations in Free Fatty Acids, Excitatory Amino Acids, and Motor Function Through An Opiate-Receptor-Mediated Mechanism", The Journal of Neuroscience (1990), 10(12), pp. 3793-3800, Bakshi et al
  • "Methylprednisolone or naloxone treatment after acute spinal cord injury: 1-year follow-up data", J. Neurosurg vol. 76 pp. 23-31 (1992), Bracken et a
loading...


View Patent Images (PDF)
(Registered users only)
 
Forgot password?
Register here